Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,841.00 | 69.00 | 0.79% |
| CAC 40 | 7,662.59 | 3.32 | -0.04% |
| DAX 40 | 23,673.29 | 236.32 | -0.99% |
| Dow JONES (US) | 44,494.94 | 400.17 | 0.91% |
| FTSE 100 | 8,785.33 | 24.37 | 0.28% |
| HKSE | 24,186.73 | 114.45 | 0.48% |
| NASDAQ | 20,202.89 | 166.84 | -0.82% |
| Nikkei 225 | 39,780.77 | 205.56 | -0.51% |
| NZX 50 Index | 12,784.29 | 49.76 | 0.39% |
| S&P 500 | 6,198.01 | 6.94 | -0.11% |
| S&P/ASX 200 | 8,610.40 | 69.30 | 0.81% |
| SSE Composite Index | 3,454.21 | 3.54 | -0.10% |